Kawai Shigeto | Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
スポンサーリンク
概要
関連著者
-
岡部 尚文
日本ロシュ研究所
-
Okabe H
Hanno Research Center Taiho Pharmaceutical Co. Ltd.
-
岡部 尚文
日本ロシュ(株)研究所抗癌剤研究部
-
Yamada‐okabe H
Department Of Oncology Nippon Roche Research Center
-
Yamada Okabe
Pharmaceutical Research Department Chugai Pharmaceutical
-
Yamada Okabe
Pharmaceutical Research Department Iii Kamakura Research Laboratories
-
Yamada-okabe Hisafumi
Department Of Mycology Nippon Roche Research Center
-
Yamada-okabe Hisafumi
Dept. Of Mycology Nippon Roche Reserch Center
-
Ozaki S
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Kawai Shigeto
Pharmaceutical Research Department Chugai Pharmaceutical
-
岡部 尚文
中外製薬(株)創薬企画推進部
-
Ozaki Shuji
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Kawai Shigeto
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
OZAKI Shuji
Tokushima University
-
MATSUMOTO Toshio
Tokushima University
-
Matsumoto Toshio
Department Of Medicine And Bioregulatory Sciences Institute Of Health Biosciences The University Of
-
Matsumoto Toshio
Department of Medicine and Bioregulatory Sciences, IHBS, the University of TOKUSHIMA Graduate school
-
Fujii Etsuko
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
Fujii Etsuko
Safety Assessment Department Chugai Pharmaceutical
-
Ozaki Shuji
Department of Medicine and Bioregulatory Sciences, Institute of Health Biosciences, The University o
-
KAWAI Shigeto
Pharmaceutical Research Department, Chugai Pharmaceutical
-
AZUMA Yumiko
Pharmaceutical Research Department, Chugai Pharmaceutical
-
FURUGAKI Kou
Pharmaceutical Research Department, Chugai Pharmaceutical
-
KOSAKA Masaaki
Tokushima Red Cross Blood Center
-
YAMADA OKABE
Pharmaceutical Research Department, Chugai Pharmaceutical
-
Matsumoto Toshio
Department Of Medicine And Bioregulatory Sciences Graduate School Of Medical Sciences University Of
-
Azuma Yumiko
Pharmaceutical Research Department Chugai Pharmaceutical
-
Furugaki Kou
Pharmaceutical Research Department Chugai Pharmaceutical
-
Kosaka M
First Department Of Physiology Kinki University School Of Medicine
-
ISHIGURO Takahiro
Pharmaceutical Research Department 3, Chugai Pharmaceutical Co. Ltd
-
HABU Kiyoshi
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
SUGIMOTO Masamichi
Pharmaceutical Research Department 3, Chugai Pharmaceutical Co. Ltd
-
SHIRAIWA Hirotake
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
IIJIMA Shigeyuki
Genome Antibody Product Research Department, Chugai Pharmaceutical Co. Ltd
-
YAMADA OKABE
Research Planning and Coordination Department, Chugai Pharmaceutical Co. Ltd
-
Yamada Okabe
Research Planning And Coordination Department Chugai Pharmaceutical Co. Ltd
-
Iijima Shigeyuki
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Shiraiwa Hirotake
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Ishiguro Takahiro
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
Sugimoto Masamichi
Pharmaceutical Research Department 3 Chugai Pharmaceutical Co. Ltd
-
Habu Kiyoshi
Genome Antibody Product Research Department Chugai Pharmaceutical Co. Ltd
-
Matsumoto Toshio
Department Of Medicine And Bioregulatory Science(the First Department Of Internal Medicine) School O
-
Yamada-Okabe Hisafumi
Research Planning and Coordination Department, Chugai Pharmaceutical Co. Ltd
-
Ozaki Shuji
Department Of Internal Medicine Tokushima Prefectural Central Hospital
-
Yamada-Okabe Hisafumi
Pharmaceutical Research Department, Chugai Pharmaceutical
-
MATSUMOTO Toshio
Department of Medicine and Bioregulatory Science (the First Department of Internal Medicine), School of Medicine, The University of Tokushima
著作論文
- Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models
- A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients